Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM 100

3,750.00p
   
  • Change Today:
      40.00p
  • 52 Week High: 5,060.00p
  • 52 Week Low: 3,225.00p
  • Currency: UK Pounds
  • Shares Issued: 5.22m
  • Volume: 3,849
  • Market Cap: £195.74m

Bioventix ups dividend on improved profits

By Iain Gilbert

Date: Monday 26 Mar 2018

LONDON (ShareCast) - (ShareCast News) - AIM-quoted pharmaceuticals company Bioventix saw revenues and profits move ahead in the first half of its trading year, leading the company to boost its first interim dividend by 20%.
Underlying revenues at Bioventix grew 13% to £3.5m, thanks in no small part to an improved performance in the "important emerging market" that is China, pushing pre-tax profits up 36% to £3.4m as a result.

During the half, an internal audit undertaken by one of Bioventix's customers identified a back-dated royalty stream of £772,391, owed to the firm for work completed between 1 July 2014 to 30 June 2017 and therefore, outside the current reporting period.

Vitamin D antibody sales continued at the same healthy levels seen in the last half of its previous trading year and gained approximately £400,000 year-on-year.

Growth in other antibody sales, such as progesterone, drug antibodies, contract NT-proBNP, also amounted to roughly £400,000, meaning the combined effect of the improved sales was "more than sufficient" to make up for the £400,000 of revenue lost due to a previously reported terminated revenue stream.

For the six months ended 31 December, Bioventix announced a first interim dividend of 25p.

"We are pleased with the continued success of our vitamin D antibody and the remainder of the core antibody business. We remain optimistic about our troponin project and the success of Siemens as their product launches around the world and we look forward to further progress in the second half of the year," said chief executive Peter Harrison on Monday.

As of 1020 GMT, shares had collected 12.90% to 2,320p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,750.00p
Change Today 40.00p
% Change 1.08 %
52 Week High 5,060.00p
52 Week Low 3,225.00p
Volume 3,849
Shares Issued 5.22m
Market Cap £195.74m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
67.17% below the market average67.17% below the market average67.17% below the market average67.17% below the market average67.17% below the market average
36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average36.00% above the sector average
Price Trend
14.7% below the market average14.7% below the market average14.7% below the market average14.7% below the market average14.7% below the market average
42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average42.86% above the sector average
Income
2.30% above the market average2.30% above the market average2.30% above the market average2.30% above the market average2.30% above the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Growth
43.01% below the market average43.01% below the market average43.01% below the market average43.01% below the market average43.01% below the market average
17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average17.65% below the sector average

Bioventix Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 07-Nov-24 11-Apr-24
Paid 21-Nov-24 26-Apr-24
Amount 87.00p 68.00p

Trades for 22-Nov-2024

Time Volume / Share Price
16:01 100 @ 3,794.00p
16:01 500 @ 3,750.00p
15:18 190 @ 3,751.00p
14:59 140 @ 3,794.00p
13:45 840 @ 3,799.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page